Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

#3818

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Aim(s): To assess the clinical value of SSAs in patients with PanNETs ≤2cm.

Materials and methods: Data from patients (pts) with sporadic, NF, G1-G2 PanNETs≤2cm were retrospectively collected. Median progression-free survival (mPFS) and response rate (RR) were analysed in SSA group and AS group.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,